One Value-Priced Biotechnology Giant
97646
The Motley Fool - As investors waited anxiously for Amgen's (Nasdaq: AMGN - News) earnings report, the United Kingdom's high court snuck in with a stinker. It ruled that Transkaryotic Therapies (Nasdaq: TKTX - News) and Sanofi-Aventis (NYSE: SNYT - News) did not infringe on the patent for EPO, Amgen's anemia treatment (which accounts for 27% of its sales), and ruled the patent invalid.
273384
Fresh after taking the performance crown and capping a five-year, $100 million R&amp;D effort, IBM today announced that Blue Gene is officially going on sale with a starting price of $1.
711588
A biotech startup receives a pile of cash to develop a technology it says can prevent people from getting diseases.
572919
Biotech titan Genzyme (Nasdaq: GENZ) has its roots in the treatment of rare genetic diseases and also has a significant presence in the treatment of renal diseases and providing diagnostic testing services.
138104
Human Genome Sciences could see more than $180 million from a new deal with drug maker GlaxoSmithKline. Glaxo has acquired exclusive rights to an experimental drug called Albugon, which Human Genome Sciences
226441
Biotechnology companies are betting that pairing old drugs can be a better business than inventing new ones from scratch.
466497
Adnexus Therapeutics Inc., an ambitious young biotech company in Waltham, says it is going public.
607613
Genzyme Corp. said it completed its $345 million acquisition of Bioenvision Inc. despite complaints by some Bioenvision shareholders the price the Cambridge biotech offered was too low. Genzyme initially tried to take control of the New York biotech through a tender offer, but managed to acquire only 22 percent of shares that way. Bioenvision then tried to persuade a majority ...
134759
The pet retailer combines the best of valuation worlds.
305997
The Securities and Exchange Commission is scrutinizing biotechnology companies as part of a wider effort to ensure that companies don&#39;t mislead investors
472251
In biotech investing, it pays to close your ears to all the hubbub.
438480
Credit Suisse First Boston said that an announcement from Onyx Pharmaceuticals (nasdaq: ONXX - news - people ) is &quot;good news&quot; for Genentech (nyse: DNA - news - people ) and its Avastin treatment.
509742
The company has earned its nosebleed valuation.
596564
A California company predicts it will soon be able to sequence an entire human gene map in four minutes, for just $1,000.
300694
Construction of the third laboratory building in Boston University's BioSquare life sciences research complex is underway, the first such building there to be designed for academic research and commercial businesses. To lure for-profit biotechnology companies, the $53 million, 160,000-square-foot building at 670 Albany St. has a sleek contemporary look, an energy-efficient interior, and a for-profit developer, Spaulding &amp; Slye Colliers.
245176
Cancer was the biotech's biggest success story. Now to keep growing, it needs to branch out.
550204
CHICAGO/NEW YORK  - When it comes to the price tag  for the newest biotechology drugs for cancer and other  hard-to-treat diseases, the sky is likely to remain the limit,  insurers, drugmakers and industry watchers say.